Update on medical treatment for Cushing’s disease
暂无分享,去创建一个
[1] E. Oldfield,et al. Cushing's disease: pathobiology, diagnosis, and management. , 2017, Journal of neurosurgery.
[2] M. Fleseriu,et al. Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushing’s disease: 12-month, Phase III pasireotide study , 2016, Endocrine.
[3] Jacques Young,et al. Long-term (19-month) control of urinary free cortisol with osilodrostat in patients with Cushing's disease: results from an extension to the LINC-2 study , 2016 .
[4] M. Fleseriu,et al. Medical treatment of Cushing's Disease. , 2016, Minerva endocrinologica.
[5] L. Nieman,et al. Endometrial Effects of Prolonged Therapy with the Selective Progesterone Receptor Modulator Ulipristal Acetate: A Case Report. , 2016, The Journal of reproductive medicine.
[6] L. Vilar,et al. The Role of Isotretinoin Therapy for Cushing's Disease: Results of a Prospective Study , 2016, International journal of endocrinology.
[7] M. Komada,et al. The USP8 mutational status may predict drug susceptibility in corticotroph adenomas of Cushing's disease. , 2016, European journal of endocrinology.
[8] A. Grossman,et al. Therapeutic Strategies for the Treatment of Severe Cushing’s Syndrome , 2016, Drugs.
[9] F. Karlsson,et al. Limited value of cabergoline in Cushing's disease: a prospective study of a 6-week treatment in 20 patients. , 2015, European journal of endocrinology.
[10] Jacques Young,et al. Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing’s disease , 2015, Pituitary.
[11] H. Kushner,et al. Sustained weight loss in patients treated with mifepristone for Cushing’s syndrome: a follow-up analysis of the SEISMIC study and long-term extension , 2015, BMC Endocrine Disorders.
[12] Julian R. E. Davis,et al. Effectiveness of Metyrapone in Treating Cushing's Syndrome: A Retrospective Multicenter Study in 195 Patients. , 2015, The Journal of clinical endocrinology and metabolism.
[13] L. Nieman,et al. Cushing's syndrome , 2015, The Lancet.
[14] P. Hoffmann,et al. Osilodrostat (LCI699), a potent 11β-hydroxylase inhibitor, administered in combination with the multireceptor-targeted somatostatin analog pasireotide: A 13-week study in rats. , 2015, Toxicology and applied pharmacology.
[15] A. Tabarin,et al. Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline. , 2015, The Journal of clinical endocrinology and metabolism.
[16] J. Newell-Price,et al. Therapy of endocrine disease: steroidogenesis enzyme inhibitors in Cushing's syndrome. , 2015, European journal of endocrinology.
[17] A. Grossman,et al. Emerging drugs for Cushing’s disease , 2015, Expert opinion on emerging drugs.
[18] S. Melmed,et al. Cyclin E-Mediated Human Proopiomelanocortin Regulation as a Therapeutic Target for Cushing Disease. , 2015, The Journal of clinical endocrinology and metabolism.
[19] P. Chanson,et al. Rapid control of severe neoplastic hypercortisolism with metyrapone and ketoconazole. , 2015, European journal of endocrinology.
[20] F. Ceccato,et al. Clinical use of pasireotide for Cushing’s disease in adults , 2015, Therapeutics and clinical risk management.
[21] C. Simeoli,et al. The treatment with pasireotide in Cushing’s disease: effects of long-term treatment on tumor mass in the experience of a single center , 2015, Endocrine.
[22] A. Colao,et al. Cabergoline use for pituitary tumors and valvular disorders. , 2015, Endocrinology and metabolism clinics of North America.
[23] T. Wieland,et al. Mutations in the deubiquitinase gene USP8 cause Cushing's disease , 2014, Nature Genetics.
[24] G. Arnaldi,et al. Up-to 5-year efficacy of pasireotide in a patient with Cushing’s disease and pre-existing diabetes: literature review and clinical practice considerations , 2015, Pituitary.
[25] N. Tritos,et al. Update on radiation therapy in patients with Cushing’s disease , 2015, Pituitary.
[26] M. Fleseriu,et al. Medical therapy for Cushing’s disease: adrenal steroidogenesis inhibitors and glucocorticoid receptor blockers , 2015, Pituitary.
[27] J. Bertherat,et al. Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing’s disease: results from an open-ended, open-label extension trial , 2014, Pituitary.
[28] M. Fleseriu,et al. Treatment of Cushing's disease: a mechanistic update. , 2014, The Journal of endocrinology.
[29] J. Schopohl,et al. Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III study , 2014, Clinical endocrinology.
[30] M. Buchfelder,et al. Changes in plasma ACTH levels and corticotroph tumor size in patients with Cushing's disease during long-term treatment with the glucocorticoid receptor antagonist mifepristone. , 2014, The Journal of clinical endocrinology and metabolism.
[31] M. Fleseriu,et al. Somatostatin receptor ligands and resistance to treatment in pituitary adenomas. , 2014, Journal of molecular endocrinology.
[32] M. Fleseriu,et al. Study Design of a Phase II trial of pasireotide s.c. alone or in combination with cabergoline in patients with Cushing's disease , 2014 .
[33] X. Bertagna,et al. LCI699, a potent 11β-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from a multicenter, proof-of-concept study. , 2014, The Journal of clinical endocrinology and metabolism.
[34] G. Golor,et al. Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study. , 2014, Diabetes research and clinical practice.
[35] P. Zelissen,et al. Increased long‐term remission after adequate medical cortisol suppression therapy as presurgical treatment in Cushing's disease , 2014, Clinical endocrinology.
[36] P. Chanson,et al. Ketoconazole in Cushing's disease: is it worth a try? , 2014, The Journal of clinical endocrinology and metabolism.
[37] G. Braunstein,et al. Global clinical response in Cushing’s syndrome patients treated with mifepristone , 2014, Clinical endocrinology.
[38] A. Lacroix,et al. Pasireotide monotherapy in Cushing’s disease: a single-centre experience with 5-year extension of phase III Trial , 2014, Pituitary.
[39] G. Vitale,et al. Molecular basis of pharmacological therapy in Cushing’s disease , 2014, Endocrine.
[40] L. Denaro,et al. Combination therapy for Cushing’s disease: effectiveness of two schedules of treatment. Should we start with cabergoline or ketoconazole? , 2014, Pituitary.
[41] F. Casanueva,et al. Managing Cushing’s disease: the state of the art , 2014, Endocrine.
[42] Ritu Malik,et al. Metyrapone for Long-Term Medical Management of Cushing's Syndrome , 2013, Case reports in endocrinology.
[43] S. Schulz,et al. Preoperative normalization of cortisol levels in Cushing's disease after medical treatment: consequences for somatostatin and dopamine receptor subtype expression and in vitro response to somatostatin analogs and dopamine agonists. , 2013, The Journal of clinical endocrinology and metabolism.
[44] L. Nieman. Update in the medical therapy of Cushing's disease , 2013, Current opinion in endocrinology, diabetes, and obesity.
[45] S. Mudaliar,et al. Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. , 2013, The Journal of clinical endocrinology and metabolism.
[46] F. Casanueva,et al. Managing hyperglycemia in patients with Cushing’s disease treated with pasireotide: medical expert recommendations , 2013, Pituitary.
[47] L. Katznelson. Sustained improvements in plasma ACTH and clinical status in a patient with Nelson's syndrome treated with pasireotide LAR, a multireceptor somatostatin analog. , 2013, The Journal of clinical endocrinology and metabolism.
[48] M. Fleseriu,et al. A new therapeutic approach in the medical treatment of Cushing's syndrome: glucocorticoid receptor blockade with mifepristone. , 2013, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[49] P. Chanson,et al. Management of hyperglycaemia in Cushing's disease: experts' proposals on the use of pasireotide. , 2012, Diabetes & metabolism.
[50] J. Romijn,et al. Cortisol diurnal rhythm and quality of life after successful medical treatment of Cushing’s disease , 2013, Pituitary.
[51] M. Fleseriu,et al. Mifepristone: is there a place in the treatment of Cushing’s disease? , 2013, Endocrine.
[52] F. de Jong,et al. Fluconazole inhibits human adrenocortical steroidogenesis in vitro. , 2012, The Journal of endocrinology.
[53] I. Gich,et al. A reappraisal of the medical therapy with steroidogenesis inhibitors in Cushing's syndrome , 2012, Clinical endocrinology.
[54] W. Drake,et al. Etomidate in the emergency management of hypercortisolemia. , 2012, European journal of endocrinology.
[55] J. Bertherat,et al. Efficiency and tolerance of mitotane in Cushing's disease in 76 patients from a single center. , 2012, European journal of endocrinology.
[56] I. Shimon,et al. Pituitary-directed medical therapy with pasireotide for a corticotroph macroadenoma: pituitary volume reduction and literature review , 2012, Pituitary.
[57] E. Arvat,et al. Potential role for retinoic acid in patients with Cushing's disease. , 2012, The Journal of clinical endocrinology and metabolism.
[58] M. Fleseriu,et al. Medical management of Cushing’s disease: what is the future? , 2012, Pituitary.
[59] A. Grossman,et al. Etomidate in the management of hypercortisolaemia in Cushing's syndrome: a review. , 2012, European journal of endocrinology.
[60] M. Fleseriu,et al. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. , 2012, The Journal of clinical endocrinology and metabolism.
[61] A. Colao,et al. A 12-month phase 3 study of pasireotide in Cushing's disease. , 2012, The New England journal of medicine.
[62] J. Briegel,et al. Medical suppression of hypercortisolemia in Cushing’s syndrome with particular consideration of etomidate , 2012, Pituitary.
[63] A. Mamelak,et al. EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas. , 2011, The Journal of clinical investigation.
[64] M. Culler. Somatostatin-Dopamine Chimeras: A Novel Approach to Treatment of Neuroendocrine Tumors , 2011, Hormone and Metabolic Research.
[65] P. Chanson,et al. Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing's syndrome. , 2011, The Journal of clinical endocrinology and metabolism.
[66] Shuo Lin,et al. Targeting zebrafish and murine pituitary corticotroph tumors with a cyclin-dependent kinase (CDK) inhibitor , 2011, Proceedings of the National Academy of Sciences.
[67] N. Tritos,et al. Management of Cushing disease , 2011, Nature Reviews Endocrinology.
[68] B. Ploeger,et al. Mitotane has a strong and a durable inducing effect on CYP3A4 activity. , 2011, European journal of endocrinology.
[69] D. Schteingart. Aldosterone Synthase Inhibition With LCI699: A Proof-of-Concept Study in Patients With Primary Aldosteronism , 2011 .
[70] W. Ludlam. Medical Treatment of Cushing's Syndrome: Glucocorticoid Receptor Antagonists and Mifepristone , 2011 .
[71] A. Lacroix,et al. Cabergoline monotherapy in the long-term treatment of Cushing's disease. , 2010, European journal of endocrinology.
[72] J. Ménard,et al. Aldosterone Synthase Inhibition With LCI699: A Proof-of-Concept Study in Patients With Primary Aldosteronism , 2010, Hypertension.
[73] T. Brue,et al. Medical Treatment of Cushing’s Syndrome: Glucocorticoid Receptor Antagonists and Mifepristone , 2010, Neuroendocrinology.
[74] J. Romijn,et al. Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease. , 2010, The New England journal of medicine.
[75] A. Klibanski,et al. Delayed remission after transsphenoidal surgery in patients with Cushing's disease. , 2010, The Journal of clinical endocrinology and metabolism.
[76] L. Vilar,et al. Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing’s disease , 2010, Pituitary.
[77] P. Chanson,et al. Merits and pitfalls of mifepristone in Cushing's syndrome. , 2009, European journal of endocrinology.
[78] G. Lombardi,et al. Effectiveness and safety of combined therapy with low dose ketoconazole and cabergoline in patients with Cushing's disease partially responsive to monotherapy with cabergoline , 2009 .
[79] J. Romijn,et al. Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas. , 2009, The Journal of clinical endocrinology and metabolism.
[80] P. Cappabianca,et al. The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. , 2009, The Journal of clinical endocrinology and metabolism.
[81] Y. Wang,et al. Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. , 2009, The Journal of clinical endocrinology and metabolism.
[82] S. Lamberts,et al. Somatostatin and dopamine receptors as targets for medical treatment of Cushing’s Syndrome , 2009, Reviews in Endocrine and Metabolic Disorders.
[83] L. Nieman,et al. Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. , 2008, The Journal of clinical endocrinology and metabolism.
[84] A. Ahmann,et al. Safety profile and metabolic effects of 14 days of treatment with DIO-902: results of a phase IIa multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in patients with type 2 diabetes mellitus. , 2008, Clinical therapeutics.
[85] B. Allolio,et al. Mifepristone (RU 486) in Cushing's syndrome. , 2007, European journal of endocrinology.
[86] M. Fleseriu,et al. Second-line treatment for Cushing's disease when initial pituitary surgery is unsuccessful , 2007, Current opinion in endocrinology, diabetes, and obesity.
[87] H. Hammes,et al. Long-Term Treatment of Central Cushing's Syndrome with Rosiglitazone , 2007, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.
[88] I. Lancranjan,et al. Dopamine D2 receptor gene expression in human adenohypophysial adenomas , 2001, Endocrine.
[89] F. Holsboer,et al. Retinoic acid as a novel medical therapy for Cushing's disease in dogs. , 2006, Endocrinology.
[90] W. Schima,et al. Long term control of hypercortisolism with fluconazole: case report and in vitro studies. , 2006, European journal of endocrinology.
[91] E. Arvat,et al. Effect of protracted treatment with rosiglitazone, a PPARγ agonist, in patients with Cushing's disease , 2006, Clinical endocrinology.
[92] L. Nieman,et al. Cushing's syndrome , 2005 .
[93] L. Nieman,et al. Cushing’s Syndrome , 2019, Canadian Family Practice Guidelines.
[94] C. Brain,et al. Efficient Short-Term Control of Hypercortisolaemia by Low-Dose Etomidate in Severe Paediatric Cushing’s Disease , 2005, Hormone Research in Paediatrics.
[95] D. Hoyer,et al. Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells. , 2005, American journal of physiology. Endocrinology and metabolism.
[96] F. Trimarchi,et al. Effects of chronic administration of PPAR-gamma ligand rosiglitazone in Cushing's disease. , 2004, European journal of endocrinology.
[97] J. Kros,et al. Dopamine receptor expression and function in corticotroph pituitary tumors. , 2004, The Journal of clinical endocrinology and metabolism.
[98] G. Fava,et al. Effect of the Serotonin Antagonists Ritanserin and Ketanserin in Cushing's Disease , 2000, Pituitary.
[99] A B Atkinson,et al. Diagnosis and complications of Cushing's syndrome: a consensus statement. , 2003, The Journal of clinical endocrinology and metabolism.
[100] J. Jørgensen,et al. Expression of somatostatin receptors on human pituitary adenomas in vivo and ex vivo , 2001, Journal of endocrinological investigation.
[101] R. Reznek,et al. Emergency and prolonged use of intravenous etomidate to control hypercortisolemia in a patient with Cushing's syndrome and peritonitis. , 1998, The Journal of clinical endocrinology and metabolism.
[102] M. Buchfelder,et al. Octreotide exerts different effects in vivo and in vitro in Cushing's disease. , 1994, European journal of endocrinology.
[103] N. Shimizu. [Cushing's disease]. , 1993, Nihon rinsho. Japanese journal of clinical medicine.
[104] A. Grossman,et al. Short and long‐term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome , 1991, Clinical endocrinology.
[105] S. Lamberts,et al. Rapid reversal of acute psychosis in the Cushing syndrome with the cortisol-receptor antagonist mifepristone (RU 486). , 1991, Annals of internal medicine.
[106] B. Allolio,et al. Infusion of low dose etomidate: correction of hypercortisolemia in patients with Cushing's syndrome and dose-response relationship in normal subjects. , 1990, The Journal of clinical endocrinology and metabolism.
[107] X. Bertagna,et al. Transient inhibition of RU 486 antiglucocorticoid action by dexamethasone. , 1990, The Journal of clinical endocrinology and metabolism.
[108] J. Loeffler,et al. Ketoconazole inhibits corticotropic cell function in vitro. , 1988, Endocrinology.
[109] A. Henniker,et al. THE EFFECT OF o,p'‐DDD ON ADRENAL STEROID REPLACEMENT THERAPY REQUIREMENTS , 1987, Clinical endocrinology.
[110] X. Bertagna,et al. Pituitary-adrenal response to the antiglucocorticoid action of RU 486 in Cushing's syndrome. , 1986, The Journal of clinical endocrinology and metabolism.
[111] X. Bertagna,et al. The new steroid analog RU 486 inhibits glucocorticoid action in man. , 1984, The Journal of clinical endocrinology and metabolism.
[112] J. Ratcliffe,et al. DIRECT IN VITRO INHIBITION OF ADRENAL STEROIDOGENESIS BY ETOMIDATE , 1983, The Lancet.
[113] D. Feldman,et al. Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes. , 1983, The Journal of clinical investigation.
[114] S. Lamberts,et al. Adrenocorticotropin-secreting pituitary adenomas originate from the anterior or the intermediate lobe in Cushing's disease: differences in the regulation of hormone secretion. , 1982, The Journal of clinical endocrinology and metabolism.
[115] N. Shimizu. [Treatment of Cushing's disease]. , 1978, Nihon rinsho. Japanese journal of clinical medicine.
[116] H. Cushing. The basophil adenomas of the pituitary body. , 1932, Annals of the Royal College of Surgeons of England.
[117] W. Manderson. Q fever; report of a case. , 1949, Lancet.